With increased interest in clinical proteomics-the comparative investigation of differential protein expression patterns for use in the diagnostic and prognostic assessment of disease states-the demand for techniques that can readily identify changes in select proteome components is greater than ever before. This article describes a targeted proteomics approach to recover and quantify C-reactive protein (CRP) directly from human plasma. CRP, a putative biomarker for cardiac health, was isolated from microliter volumes of human plasma by using novel proteomics tools that combine micro-scale affinity capture with matrix assisted laser desorption/ionization time-offlight mass spectrometry (MALDI-TOF MS) detection. Native CRP was analyzed along with serum amyloid P component (SAP) and retinol binding protein (RBP), that were intentionally targeted to generate a selected protein expression profile. A number of qualitative changes were readily observed within these profiles, including micro heterogeneity in the SAP glycan, C-terminally truncated versions of RBP, and detection of a novel truncated variant of CRP. After quantitative validation of increasing plasma CRP concentrations, the approach was applied to the analysis of eight plasma samples obtained from individuals with known medical histories. The result of the analyses are eight protein profiles, revealing increasing CRP levels that can be associated with individuals ailing from post-surgery inflammation, chronic rheumatoid arthritis, and recent acute myocardial infarction. The technique described in this article lays the foundation for selected protein profiling for use in biomarker discovery, as well as in clinical and diagnostic applications.
Introduction
Clinical proteomics focuses on the use of rapid fractionation approaches in combination with mass spectrometry (MS) to directly profile human biofluids, plasma in particular. By design, these studies are meant to establish protein signatures, in the form of mass spectra, that are able to distinguish between healthy and diseased states in individuals. Indeed, numerous pioneering investigations have shown clinical proteomics to be one of the most promising new approaches for defining diagnostic signatures related to ovarian, breast, prostate and lung cancers (1) (2) (3) . However, a particular concern of these studies is that many of the profiling approaches distinguish healthy from diseased states based on computer learning algorithms that may not identify a landmark mass-to-charge (m/z) value as actually being a protein species. Such an approach may be misleading if the m/z values used have no corresponding peptide signals. Moreover, to date no clinical proteomics study has independently "rediscovered" known biomarkers of various cancers (e.g., prostate specific antigen [PSA] is not detected in individuals suffering from prostate cancer). In missing, or not specifically targeting these proteins as part of the profiling, these studies do not take full advantage of past clinical/diagnostic studies, the results of which are the basis of numerous current diagnostic assays (4) . Accordingly, there exists a growing demand to discover and identify proteins for use as putative biomarkers, and at the same time detect proteins that are presently used (and validated) as diagnostic species (5) .
Given that the identity of the biomarker is known (either old or newly found), it is clearly more efficient to construct assays that target them directly, rather than to continue to assay samples using the global discovery methodologies. A foremost advantage to using a targeted approach in combination with mass spectrometry is the ability to significantly improve the limit of detection of the assay. Specifically, affinity approaches are able to selectively concentrate target proteins prior to mass spectrometry, the result of which is a highly purified form of the target protein entering the mass spectrometer without any accompanying interferences stemming from the presence of other proteins (e.g., ion suppression or overlapping signals). A second advantage is the use of targeted high-performance mass spectrometric assays to discern and characterize genomic and epigenomic differences that are found in proteins. Because of genetic and posttranslational variations, any protein under investigation has the potential of existing within or between individuals as multiple species. Mass spectrometry of highly purified proteins has been used for many years to both detect and characterize and/or identify these variations (6) . This long-standing ability is ideally complimented by a simple fractionation approach that can be used to selectively concentrate chosen proteins directly from biological milieu.
Thus, findings made through efforts in the fields of clinical biology and medicine, including proteomics, stand to be improved upon by: (1) knowing the identity of the signature/biomarker proteins, (2) reducing the signature profile to its essential components, and (3) detecting structural and quantitative variations-present in natural populationsencountered in the proteins. Moreover, proteomics technologies responsive to these needs must be readily applied in the analysis of hundreds-to-thousands of samples.
Overview of the Mass Spectrometric
Immunoassay Process
Previous works have described a hybrid protein analysis technology-mass spectrometric immunoassay (MSIA)-that is used to selectively retrieve target proteins from complex biological milieu for mass spectrometric characterization and quantification (7) (8) (9) (10) . Figure 1 gives a brief overview of the process. As applied here, a human plasma sample is repeatedly drawn and expelled through a pipettor tip containing a stationary phase to which an affinity ligand is covalently bound (termed MSIA-Tip). After rinsing, MALDI matrix is drawn into the MSIA-Tip, breaking the affinity interaction. The resulting matrix/ analyte mixture is deposited directly onto a mass spectrometer target for subsequent matrixassisted laser desorption/ionization time-offlight mass spectrometry (MALDI-TOF MS). Analyte detection/characterization is essentially a combination of affinity isolation via immobilized antibodies and characterization of retained species by MALDI-TOF MS. In this sense, target proteins and their variants are selectively concentrated from plasma, and MALDI-TOF MS is used to (1) unambiguously identify the wild-type target protein by detection at a known molecular weight and (2) recognize the presence of variants retained by the antibody at masses shifted away from the wildtype protein. This ability forms the basis of an assay capable of identifying protein variants resulting from posttranslational modifications (9), pointmutations (10), or truncations (11) (12) (13) . The simultaneous analysis of mass-resolved species lays the foundation for the rigorous quantification of a target protein (14) or the development of multiple-analyte assays (7) .
Presented here is the development of a multi-analyte MSIA for use in the expression profiling of a select group of proteins-C-reactive proteins (CRP), retinol binding protein (RBP), and serum amyloid P component (SAP) (and their variants)-present in human plasma. The central target in these analyses is CRP, a known clinical protein biomarker of inflammation that has been determined to have short-and long-term predictive value of patient outcomes with cardiovascular disease and the development of coronary events that can be used to identify the onset and recurrence of myocardial infarction (MI) (15) (16) (17) (18) , stroke (19) (20) , and angina (21) (22) . The two other protein species, RBP and SAP were chosen as complement proteins (for use in normalizing the MSIA profiles between individuals) based on a few simple criteria. First, for optimization of MALDI-TOF MS conditions (e.g., matrix, delayed-extraction), the proteins must have similar, but fully resolved molecular weights. Second, the complement proteins are found in healthy populations at roughly equivalent and reasonably stable concentrations. Lastly, MSIA conditions for the complement proteins (e.g., extraction and rinses) are the same as for the target protein.
Materials and Methods

Samples
Plasma samples from eight individuals (five males and three females betweent the ages of 26 and 48) were acquired following a procedure approved by the IBI's Institutional Review Board (IRB), and only after each subject had signed an Informed Consent form. Samples were acquired, under sterile conditions, through a lancet-punctured finger using two nonheparinized (75 µL volume) microcolumns (Drummond Scientific Co., Broomall, PA). Each 150 µL whole blood sample collected was immediately combined with 200 µL HEPES buffered saline (10 mM HEPES, 150 mM NaCl, pH 7.4 [HBS]) containing 50 mM ethylenediamine tetraacetic acid (EDTA) and 2 µL of a protease inhibitor cocktail set II (Calbiochem, San Diego, CA), and centrifuged for 2 min (at 7000 rpm/2500g) to pellet red blood cells. The supernatant (diluted plasma, 250 µL) was decanted from each sample and stored at -70°C until ready for use.
For the standard addition quantification experiments, a single plasma sample was dispersed into eight 25 µL aliquots. Increasing amounts (0 through 7 aliquots of 14 µL) of 0.0183 mg/mL standard solution containing highly purified human C-reactive protein (Calbiochem, San Diego, CA) were added to the plasma aliquots. Each aliquot was then brought to 300 µL with HBS-EDTA buffer.
MSIA Analysis
The plasma samples were addressed in parallel using a multi channel pipettor, using CDI (1,1'-carbonyldiimidazole)-activated MSIA-Tips prepared and derivatized with polyclonal antibodies specific towards retinol binding protein, C-reactive protein and serum amyloid P component (DakoCytomation, Carpinteria, CA), as previously described (8) . Sample incubation consisted of 50 cycles (aspiration and dispensing) of 150 µL of the sample through each MSIA-Tip. After incubation, the MSIA-Tips were thoroughly rinsed using HBS, 10 cycles of 150 µL; double distilled water, 5 cycles of 150 µL; 20% acetoniltrile/2M ammonium acetate, 10 cycles of 150 µL; and finally with double distilled water, 15 cycles of 150 µL. Retained proteins were eluted by drawing 4 µL of MALDI matrix solution (saturated aqueous solution of sinapic acid (SA), in 33% (v/v) acetonitrile, 0.4% (v/v) trifluoroacetic acid) into each tip and depositing the eluates directly onto a 96-well formatted hydrophobic/hydrophilic contrasting MALDI-TOF target (14) . Samples were allowed to air dry prior to insertion of the MALDI target into the mass spectrometer. The total time required for preparation of the samples was less than 10 min.
MALDI-TOF MS
Intact protein expression profiling was performed on a Bruker Biflex III MALDI-TOF mass spectrometer operating in linear delayed-extraction mode with 25.50 kV full accelerating potential. Draw-out pulses of 2.175 kV (900 ns delay) were used for parent protein analysis. Mass spectra were manually acquired. Five spectra from each spot were acquired and averaged for relative quantitative measurements.
Results
Individual and Multi-Protein MSIA Assays
Assays for the individual proteins were developed and investigated to gauge compatibility and to check for any unforeseen interferences. Figure 2 shows a comparison between the MSIA analyses of human plasma for CRP, RBP, SAP, and a MALDI-TOF MS analysis of the stock plasma (diluted 100-fold with water, taken prior to any MSIA extraction). In each case, the target species was selectively isolated to the exclusion of higher concentration plasma proteins that are generally observed in the analysis of human plasma with no prior fractionation (i.e., albumin, apolipoproteins) (Fig. 2D) . Additionally, there is no signal overlap between the chosen proteins (i.e., the three proteins register at distinct m/z regions in the mass spectra), nor are any interferences observed in the spectra, owing to, for example, nonspecific binding.
Based on the compatibility of the individual analyses, a multi-analyte MSIA was constructed by linking antibodies targeting the three species to the same MSIA-Tip. Figure 3 shows the results of using the assay on a plasma sample taken from a healthy 29-yr-old male (Individual No. 
Validation of CRP Response
As the foremost purpose of the assay was that of viewing modulation in CRP, a standard addition approach was used to confirm a direct relationship between CRP signal intensity and concentration. Eight samples (using the Individual No. 5 sample) were prepared to contain increasing amounts of CRP standard. 
Profiling Relative to Medical History
Plasma samples from eight individualswith knowledge of their medical dispositionwere screened using the RBP-CRP-SAP assay. Profiles comparable in detail to that shown in Figure 3 were obtained for each individual. Figure 6 shows a simple comparison of the profiles where ion signals for the eight species were normalized to the wt-SAP signal, seven data points for each individual with the eighth serving to normalize between individuals. Signal for each species can be evaluated on its own, or as part of the collective profile, and put into perspective with regard to the origin of the protein species and the medical history surgery when the plasma sample was collected, whereas subject No. 6 suffered from chronic rheumatoid arthritis and No. 8 had recently suffered an acute myocardial infarction. The elevated levels of CRP in these individuals is in agreement with the fact that CRP is an established acute-phase protein known to respond to both immediate and chronic inflammation (24) , as well as a marker of cardiovascular health (25) . Although not previously cataloged as an endogenous species, the truncated CRP variant mimics the CRP response in these individuals, which may be expected considering that the two species are linked biologically. Individual No. 7 was noted to have elevated levels of all the signals in the profile, with the exception of the wt-SAP (normalization) signal. This observation was consistent with the individual having a below average level of the fully glycosylated SAP, the cause of which remains unclear.
Conclusion
The need for targeted mass spectrometric analysis of human proteins increases dramatically as the field of clinical proteomics evolves from the discovery phase to validation and application. Given here has been the development and use of a proteomics approach for the expression profiling a select group of proteins from human plasma. Importantly, the approach is able to yield information towards a specific question. The RBP-CRP-SAP MSIA was designed to recognize, and if chosen rigorously quantify, changes in the plasma concentration of CRP. Notwithstanding this ability, the profiling approach also contains an element of discovery. As a result of genetic polymorphism, splice variants, and posttranslational modifications, any particular protein has the potential of being produced as one of numerous different variants. Moreover, additional variants can be created by the natural metabolism/catabolism of the protein after expression. As a case in-point, the three proteins under investigation, RBP-CRP-SAP, actually register as eight identifiable and consistently observed species in the expression profiling. The ability to readily monitor such variants clearly adds an additional dimension of performance to an otherwise routine analysis, which in turn allows subtle changes in protein structure to be discovered and investigated. Given these abilities and their general application in number, MSIA is viewed as an exceptional approach for the expression profiling of select protein targets in human plasma to determine qualitative and quantitative changes between individuals. Such selected expression profiling stands to find use in population screening and validation efforts subsequently derived from discoveries made through ongoing comparative proteomics studies.
